A Mobile Health Intervention in Pulmonary Arterial Hypertension (mHealth)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03069716 |
|
Recruitment Status :
Completed
First Posted : March 3, 2017
Results First Posted : June 24, 2021
Last Update Posted : June 25, 2021
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Pulmonary Arterial Hypertension Idiopathic Pulmonary Arterial Hypertension Heritable Pulmonary Arterial Hypertension Associated Pulmonary Arterial Hypertension | Device: Smartphone Text Messaging Device: Fitbit Charge HR | Not Applicable |
Patients with pulmonary arterial hypertension (PAH) have severely reduced exercise capacity and reduced quality of life. At diagnosis, most PAH patients are New York Heart Association (NYHA) functional class III with symptoms of fatigue and shortness of breath with less than ordinary activity. Physical activity confers multiple benefits relevant to PAH pathophysiology including improvements in endothelial function, energy metabolism, and right ventricular (RV) function. Increasing physical activity is highly efficacious in PAH, resulting in six-minute walk distance (6MWD) improvement that exceeds the effect of medications.
The goal of this proposal is to adapt and test the feasibility of our mHealth intervention to increase physical activity in a geographically diverse PAH population. In secondary aims, we will assess conventional PAH trial outcomes (6MWD, quality of life) and physiologic mechanisms by which increasing activity may improve exercise capacity.
The investigator hypothesizes that an mHealth intervention is feasible and will increase physical activity in subjects with PAH. This study proposes a randomized trial of unblinded step tracking with smart texts tracking for 12 weeks. Participants will wear a display-free triaxial accelerometer, which will continuously transmit data to a compatible smartphone (owned by 75% of our PAH population). Efficacy endpoints have been selected to mirror FDA criteria for drug approval in PAH. The following aims will be tested:
Aim 1: To test the feasibility of an mHealth intervention to increase step counts in patients with PAH. Fifty PAH patients will be randomized to the mHealth intervention or usual activity for 12 weeks. The primary endpoint will be daily step count during Week 12. Secondary endpoints will assess step target achievement, daily activity time, and aerobic time. The fidelity of data collection and text transmission will also be assessed.
Aim 2: To examine the effect of an mHealth intervention on exercise capacity and quality of life. Participants will complete a six minute walk test and the emPHasis-10 questionnaire at baseline and 12 weeks. The primary endpoint will be six minute walk distance. Secondary endpoints will be emPHasis-10 quality of life scale score, Borg dyspnea score, and resting heart rate.
Aim 3: To examine the effect of an mHealth intervention on mechanisms of improved exercise capacity. Subjects will undergo echocardiography, blood draw, and body composition assessment. The primary endpoint will be RV longitudinal strain. Secondary endpoints will be the homeostatic model assessment of insulin resistance, lean muscle and fat mass, and B-type natriuretic peptide.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 49 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Intervention Model Description: | Randomization will occur after a two-week run-in period to improve ability to identify a true baseline step count and account for potential dropout. Participants will be assigned to either the smartphone text messaging or no smartphone text messaging arms in a random manner until 25 participants are enrolled into each arm. Permuted block randomization stratified by functional class (I/II vs. III) will be used to ensure approximate balance of treatment groups within each stratum over time. Randomization will be performed in small blocks, which vary in size. Investigators will be unaware of the size or order of the blocks. Randomization will occur through REDCap by a study coordinator. Although the texting intervention will end after Week 12, subjects in both groups will be asked to continue wearing the Fitbit Charge HR device for an additional 3 weeks to determine whether withdrawal of the texting intervention results in a reduction in step counts. |
| Masking: | Triple (Care Provider, Investigator, Outcomes Assessor) |
| Masking Description: | Investigators are blinded. Study personnel conducting 6MWT and echo will be blinded. |
| Primary Purpose: | Treatment |
| Official Title: | A Mobile Health Intervention in Pulmonary Arterial Hypertension |
| Actual Study Start Date : | August 2, 2017 |
| Actual Primary Completion Date : | April 24, 2020 |
| Actual Study Completion Date : | April 24, 2020 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Smartphone Text Messaging
Group receives personalized, health coaching via "smart" text messages.
|
Device: Smartphone Text Messaging
A HIPPA compliant text messaging platform is linked to the Fitbit Application Program Interface. Real time activity data will be transmitted from the subject's smartphone to our mHealth platform via cellular network. Subjects will receive 3 texts/day in sync with their preferred morning, lunch, and evening leisure schedule (defined at enrollment). These texts will use personal, disease-specific, and provider information to deliver 2 types of messages customized to the current step count and sent in equal proportion. Messages are designed to facilitate self-awareness, reinforce step targets, and link physical activity with a reward or memorable cue.
Other Name: mHealth activity intervention Device: Fitbit Charge HR The Fitbit Charge HR tri-axial accelerometer will be used to continuously gather data on physical activity, heart rate, and sleep. This device provides feedback in units of activity (steps, stairs climbed, activity time, and exercise time) and heart rate (per second when active, per 5 seconds when inactive). It has been validated against research devices in free-living conditions and is relatively inexpensive.
Other Name: Digital Activity Tracker |
|
No Smartphone Text Messaging
Group does not receive personalized, health coaching via "smart" text messages.
|
Device: Fitbit Charge HR
The Fitbit Charge HR tri-axial accelerometer will be used to continuously gather data on physical activity, heart rate, and sleep. This device provides feedback in units of activity (steps, stairs climbed, activity time, and exercise time) and heart rate (per second when active, per 5 seconds when inactive). It has been validated against research devices in free-living conditions and is relatively inexpensive.
Other Name: Digital Activity Tracker |
- Daily Step Count [ Time Frame: Baseline to 12 weeks ]Change from baseline mean daily step count at week 12.
- Six Minute Walk Test Distance [ Time Frame: Baseline to 12 weeks ]Change from baseline of six minute walk test distance (meters) at week 12.
- Right Ventricle (RV) Strain [ Time Frame: Baseline to 12 weeks ]Change from baseline of RV free wall longitudinal strain at week 12.
- Percentage of Days Participants Met Their Daily Step Count Goal [ Time Frame: Baseline to 12 weeks ]All participants were provided with an Fitbit Charge Heart Rate mobile device to monitor daily step counts, activity time, and aerobic time. The daily goal was communicated via text to the intervention group and was the baseline step count average for the control group. Increased daily goal attainment indicates increased activity level
- Daily Aerobic Time [ Time Frame: Baseline to 12 weeks ]Change in minutes of activity per day between Week 12 and Baseline
- Change From Baseline at Week 12 in emPHasis-10 Questionnaire Score [ Time Frame: Baseline to 12 weeks ]Quality of life was assessed using the emPHasis-10 questionnaire, a disease-specific self-administered 10-question questionnaire designed for routine assessment of health-related quality of life in pulmonary hypertension. Total score can range from 0 to 50, with higher scores indicating a worse quality of life. Change from Baseline was calculated as the value at Week 12 minus the value at Baseline. The Week 12 value was defined as the last assessment at or prior to Week 12.
- Change From Baseline on the SF-36 Mental Component Summary (MCS) Score [ Time Frame: Baseline to 12 weeks ]SF-36 consists of 36 questions measuring 8 health domains: physical functioning, bodily pain, role limitations due to physical problems, role limitations due to emotional problems, general health perceptions, mental health, social function, and vitality. The patient's responses are solicited using Likert scales that vary in length, with 3-6 response options per item. The SF-36 can be scored into the 8 health domains named above and two overall summary scores: physical component summary (PCS) and mental component summary (MCS) scores. The domain and summary scores range from 0 to 100; higher scores indicate better levels of function and/or better health
- Change From Baseline to Week 12 in Borg Dyspnea Score [ Time Frame: Baseline to 12 weeks ]The Borg Dyspnea score is a self-rating scale to evaluate the severity of dyspnea (from 0 "no shortness of breath at all" to 10 "very, very severe / maximal" shortness of breath). The scale was completed at the beginning and conclusion of each 6-minute walk test at baseline and at Week 12. Median change from baseline in scoring was reported.
- Resting Heart Rate [ Time Frame: Baseline to 12 weeks ]Change in heart rate between Week 12 and Baseline
- Total Lean Mass [ Time Frame: Baseline to 12 weeks ]Change from baseline lean mass at week 12.
- Insulin Resistance [ Time Frame: Baseline to 12 weeks ]Insulin resistance measured by the Homeostatic Model Assessment for Insulin Resistance insulin resistance score (HOMA-IR) utilizing the formula: fasting plasma glucose (mmol/l) times fasting serum insulin (mU/l) divided by 22.5. Low HOMA-IR values indicate high insulin sensitivity, whereas high HOMA-IR values indicate low insulin sensitivity (insulin resistance).
- BNP [ Time Frame: Baseline to 12 weeks ]Change from baseline B-type natriuretic peptide level at week 12.
- Change From Baseline on the SF-36 Physical Component Summary (PCS) Score [ Time Frame: Baseline to 12 weeks ]SF-36 consists of 36 questions measuring 8 health domains: physical functioning, bodily pain, role limitations due to physical problems, role limitations due to emotional problems, general health perceptions, mental health, social function, and vitality. The patient's responses are solicited using Likert scales that vary in length, with 3-6 response options per item. The SF-36 can be scored into the 8 health domains named above and two overall summary scores: physical component summary (PCS) and mental component summary (MCS) scores. The domain and summary scores range from 0 to 100; higher scores indicate better levels of function and/or better health
- Minutes of Moderate-vigorous Activity [ Time Frame: Baseline to 12 Weeks ]Change in minutes between Week 12 and Baseline
- Visceral Fat Volume [ Time Frame: Baseline to Week 12 ]Change in fat volume between Week 12 and Baseline
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Aged 18 or older.
- Diagnosed with idiopathic, heritable, or associated (connective tissue disease, drugs, or toxins) pulmonary arterial hypertension (PAH) according to World Health Organization consensus recommendations.
- Stable PAH-specific medication regimen for three months prior to enrollment. Subjects with only a single diuretic adjustment in the prior three months will be included.
- Subjects must own a Bluetooth capable modern smartphone capable of receiving and sending text messages and an active data plan.
Exclusion Criteria:
- Prohibited from normal activity due to wheelchair bound status, bed bound status, reliance on a cane/walker, activity-limiting angina, activity-limiting osteoarthritis, or other condition.
- Pregnancy.
- Diagnosis of PAH etiology other than idiopathic, heritable, or associated.
- Forced vital capacity <70% predicted.
- Functional class IV heart failure.
- Requirement of > 1 diuretic adjustment in the prior three months.
- Preferred form of activity is not measured by an activity tracker (swimming, yoga, ice skating, stair master, or activities on wheels such as bicycling or rollerblading).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03069716
| United States, Tennessee | |
| Vanderbilt University Medical Center | |
| Nashville, Tennessee, United States, 37232 | |
| Principal Investigator: | Evan Brittain, MD, MSc | Vanderbilt University Medical Center |
Documents provided by Evan Brittain, Vanderbilt University Medical Center:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Evan Brittain, Assistant Professor of Medicine, Vanderbilt University Medical Center |
| ClinicalTrials.gov Identifier: | NCT03069716 |
| Other Study ID Numbers: |
IRB #162004 |
| First Posted: | March 3, 2017 Key Record Dates |
| Results First Posted: | June 24, 2021 |
| Last Update Posted: | June 25, 2021 |
| Last Verified: | June 2021 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Pulmonary Arterial Hypertension |
|
Pulmonary Arterial Hypertension Familial Primary Pulmonary Hypertension Hypertension Vascular Diseases |
Cardiovascular Diseases Hypertension, Pulmonary Lung Diseases Respiratory Tract Diseases |